The role of data mining in pharmacovigilance, Expert Opin Drug Saf, vol.4, issue.5, pp.929-977, 2005. ,
Principles of signal detection in pharmacovigilance, Drug Saf, vol.16, issue.6, pp.355-65, 1997. ,
Essais cliniques : Théorie, pratique et critique. 4ème édition, 2006. ,
Differences between clinical trials and postmarketing use, Br J Clin Pharmacol, vol.57, issue.1, pp.86-92, 2004. ,
Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials, Ther Innov Regul Sci, vol.52, issue.2, pp.141-58, 2018. ,
, Report of CIOMS Working Group X. Evidence Synthesis and Meta-Analysis for Drug Safety, Council for International Organizations of Medical Sciences (CIOMS), 2016.
Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions, Clin Trials Lond Engl, vol.10, issue.1, pp.20-31, 2013. ,
Meta-analysis of incidence of rare events, Stat Methods Med Res ,
, Apr, vol.22, issue.2, pp.117-149
Meta-analysis: pitfalls and hints, Heart Lung Vessels, vol.5, issue.4, pp.219-244, 2013. ,
, Thalidomide in Mann's Pharmacovigilance, Mann's Pharmacovigilance, 2014.
, History of pharmacovigilance, Mann's Pharmacovigilance, 2014.
medicine/data-mining-techniques-in-pharmacovigilance-analysis-of-the-publiclyaccessible-fda-adverse-event-re 13. World Health Organization, Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS), vol.7, pp.323-332, 1998. ,
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias, Drug Saf, vol.30, issue.10, pp.891-899, 2007. ,
Temporal trends in spontaneous reporting of unlabelled adverse drug reactions, Br J Clin Pharmacol, vol.44, issue.3, pp.299-301, 1997. ,
Under-reporting of adverse drug reactions in general practice, Br J Clin Pharmacol, vol.43, issue.2, pp.177-81, 1997. ,
Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance, Ther Innov Regul Sci, vol.52, issue.2, pp.159-69, 2018. ,
The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database, Fundam Clin Pharmacol, vol.22, issue.2, pp.127-167, 2008. ,
Under-reporting of adverse drug reactions : a systematic review, Drug Saf, vol.29, issue.5, pp.385-96, 2006. ,
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions, Pharmacoepidemiol Drug Saf, vol.11, issue.1, pp.3-10, 2002. ,
Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database, Br J Clin Pharmacol, vol.72, issue.6, pp.905-913, 2011. ,
Good Signal Detection Practices: Evidence from IMI PROTECT, Drug Saf, vol.39, pp.469-90, 2016. ,
Comparison of statistical signal detection methods within and across spontaneous reporting databases, Drug Saf, vol.38, issue.6, pp.577-87, 2015. ,
The reporting odds ratio and its advantages over the proportional reporting ratio, Pharmacoepidemiol Drug Saf, vol.13, issue.8, pp.519-542, 2004. ,
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports, Pharmacoepidemiol Drug Saf, vol.10, issue.6, pp.483-489, 2001. ,
Guideline on the use of Statistical Signal Detection Methods in the EudraVigilance Data Analysis System, 2006. ,
Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database, Drug Saf, vol.25, issue.6, pp.381-92, 2002. ,
A Bayesian neural network method for adverse drug reaction signal generation, Eur J Clin Pharmacol, vol.54, issue.4, pp.315-336, 1998. ,
Screening for adverse reactions in EudraVigilance, 2016. ,
,
Novel statistical tools for monitoring the safety of marketed drugs, Clin Pharmacol Ther, vol.82, issue.2, pp.157-66, 2007. ,
An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies, Drug Saf, vol.39, issue.1, pp.29-43, 2016. ,
,
, Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase, Br J Clin Pharmacol, vol.84, issue.10, pp.2373-83, 2018.
,
Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics, Br J Clin Pharmacol, vol.83, issue.7, pp.1544-55, 2017. ,
,
An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders, Br J Clin Pharmacol, vol.83, issue.3, pp.612-634, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01406529
Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems, Nutr Metab Cardiovasc Dis NMCD, vol.28, issue.6, pp.533-575, 2018. ,
The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from, Drug Saf, vol.37, issue.4, pp.283-94, 2006. ,
,
Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf, vol.35, pp.855-64, 2012. ,
, , 2018.
, The Council for International. Organizations of Medical Sciences. Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for their Use, 2000.
, World Health Organization. Safety of Medicines -A Guide to Detecting and Reporting Adverse Drug Reactions -Why Health Professionals Need to Take Action, 2002.
Indication bias or protopathic bias?, Br J Clin Pharmacol, vol.80, issue.4, pp.779-80, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01983159
Side-effects of antiinflammatory drugs, advances in inflammation research, 1984. ,
Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area, Eur J Clin Pharmacol, vol.70, issue.5, pp.627-662, 2014. ,
A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases, Drug Saf, vol.39, issue.3, pp.251-60, 2016. ,
Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(®), Drug Saf, vol.39, issue.7, pp.689-96, 2016. ,
Statistical power analysis for the behavioral sciences, vol.567 ,
Evaluation of regression procedures for methods comparison studies, Clin Chem, vol.39, issue.3, pp.424-456, 1993. ,
Detection of Influential Observation in Linear Regression, Technometrics, vol.19, issue.1, pp.15-23, 1977. ,
Suicidality in Children and Adolescents Being Treated With Antidepressant Medications, 2004. ,
, Information for healthcare professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate), 2007.
,
,
, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet Lond Engl, vol.382, issue.9896, pp.951-62, 2013.
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis, Lancet Lond Engl, vol.385, issue.9982, pp.2047-56, 2015. ,
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis, Lancet Lond Engl, vol.388, pp.881-90, 2016. ,
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. The BMJ [Internet, vol.359, 2017. ,
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis, JAMA, vol.316, issue.3, pp.313-337, 2016. ,